UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 1, 2003
PROTEIN DESIGN LABS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
000-19756 |
|
94-3023969 |
|
(State or other
jurisdiction of |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
|
|
|
|
|
34801
Campus Drive |
||||
|
(Address of principal executive offices) (Zip Code) |
||||
|
|
|
|
|
|
|
Registrant’s telephone number, including area code: (510) 574-1400 |
||||
Not Applicable
(Former name or former address, if changed since last report)
Item 5. Other Events
On December 1, 2003, Protein Design Labs, Inc. (“PDL”) issued a press release regarding an agreement in principle to resolve a dispute relating to PDL’s antibody humanization patents and certain of Genentech’s humanized antibodies. A copy of PDL’s press release is attached hereto as Exhibit 99.1.
Item 7. Financial Statements and Exhibits
(c) Exhibits
99.1 Press Release dated December 1, 2003.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
PROTEIN DESIGN LABS, INC. |
||
|
|
|
||
|
|
|
||
|
Date: December 1, 2003 |
By: |
/s/ Sergio Garcia-Rodriguez |
|
|
|
|
Sergio Garcia-Rodriguez |
|
3
EXHIBIT INDEX
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release dated December 1, 2003. |
4